MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
Dr. Sandeep Kunwar, Surgical Director of the California Center for Pituitary Disorders at UCSF, performing a transsphenodial resection of a pituitary adenoma. Painting by Dr. Lewis Blevins. The operating microscope, introduced by Dr. Jules Hardy
painting by Lewis Blevins, MD
From the Huffington Post By Shelby Freedman Harris, Psy.D. for YouBeauty.com We know about the benefits of a good night’s sleep — better memory, attention, concentration and a reduced risk of heart attack and stroke. Sleep improves our
Some pituitary tumors occur as a result of heritable conditions. Dr. Korbonits and her group have remarkably advanced our understanding of the genetics of inherited pituitary disorders. She has elucidated the genetic cause of acromegaly